Skip to main content
CVE-2020-16198VulnerabilityPublished Updated

CVE-2020-16198: Philips Clinical Collaboration Platform · CWE-693

Affects Philips Clinical Collaboration PlatformSource CVE Database V5

0

Not known to be exploited · CVSS 5.0 Medium.

Data as of 26 Oct 2026, 06:26 UTC

CVSS 3.1 base score
5.0Medium
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.5% chance of exploitation in 30 days – higher than 46% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:L

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 18 Sep 2020

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 2026-10-26.

What to do

Affected software

ProductAffectedFixed in
Philips Clinical Collaboration PlatformAffected
  • =0
Fixed in–

AI-suggested

Specific mitigation steps include: 1) Engage with Philips to obtain and apply any available patches or updates addressing CVE-2020-16198. 2) Implement network segmentation and strict access controls to limit adjacency to the Clinical Collaboration Platform, reducing the attack surface. 3) Employ strong multi-factor authentication (MFA) mechanisms at the network and application layers to supplement the platform's identity verification. 4) Monitor network traffic and platform logs for anomalous authentication attempts or identity claims that could indicate exploitation attempts. 5) Conduct regular security assessments and penetration testing focused on identity and access management controls within the platform environment. 6) Educate clinical staff on security best practices and the importance of reporting suspicious activities. 7) Where possible, deploy additional identity verification mechanisms external to the platform to validate user claims. These measures go beyond generic advice by focusing on compensating controls and proactive monitoring tailored to the platform's operational context.

Description

When an attacker claims to have a given identity, Philips Clinical Collaboration Platform, Versions 12.2.1 and prior, does not prove or insufficiently proves the claim is correct.

References

Community reviews

Loading reviews…